Tvardi Therapeutics
TVRD
126 hedge funds and large institutions have $559M invested in Tvardi Therapeutics in 2019 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 47 increasing their positions, 29 reducing their positions, and 21 closing their positions.
62% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 29
28% more capital invested
Capital invested by funds: $438M → $559M (+$121M)
8.98% more ownership
Funds ownership: 56.49% → 65.47% (+9%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4% less call options, than puts
Call options by funds: $20.9M | Put options by funds: $21.7M
7% less funds holding
Funds holding: 135 → 126 (-9)
29% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
+$18.7M |
| 2 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$18.6M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$18.6M |
| 4 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
+$10.9M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$5.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$5.96M |
| 2 |
RCP
Rho Capital Partners
New York
|
-$5.86M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.92M |
| 4 |
Parallax Volatility Advisers
San Francisco,
California
|
-$2.39M |
| 5 |
C
Chescapmanager
Baltimore,
Maryland
|
-$1.97M |
TVRD Hedge Fund Activity: Q2 2019 in Review
126 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q2 2019, worth a combined $559M — up 28% from $438M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of TVRD and 15 opened new positions — a net loss of 6 holders — while 29 trimmed existing stakes and 47 added.
The largest buyer was First Manhattan, adding an estimated $18.7M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $5.96M sold.
- 126 institutional investors held Tvardi Therapeutics (TVRD) as of Q2 2019, down from 135 in Q1 2019.
- Funds reported $559M of Tvardi Therapeutics stock for Q2 2019, up 28% quarter-over-quarter.
- 15 funds opened new Tvardi Therapeutics positions in Q2 2019 and 21 closed out, a net change of -6 holders.
- The largest Tvardi Therapeutics buyer in Q2 2019 was First Manhattan, an estimated $18.7M added.
- The largest Tvardi Therapeutics seller in Q2 2019 was Sphera Funds Management, an estimated $5.96M sold.
Based on aggregated 13F filings for Q2 2019.